Intranasal administration of a Schistosoma mansoni glutathione S-transferase-cholera toxoid conjugate vaccine evokes antiparasitic and antipathological immunity in mice.
Mucosal administration of Ags linked to cholera toxin B subunit (CTB) can induce both strong mucosal secretory IgA immune responses and peripheral T cell hyporeactivity. In this study, intranasal (i.n. ) administration of CTB-conjugated Schistosoma mansoni 28-kDa GST (CTB-Sm28GST) was found to protect infected animals from schistosomiasis, especially from immunopathological complications associated with chronic inflammation. Worm burden and liver egg counts were reduced in infected animals treated with the CTB-Sm28GST conjugate as compared with mice infected only, or with mice treated with a control (CTB-OVA) conjugate. However, a more striking and consistent effect was that granuloma formations in liver and lungs of mice treated with CTB-Sm28GST were markedly suppressed. Such treatment was associated with reduced systemic delayed-type hypersensitivity and lymphocyte proliferative responses to Sm28GST. Production of IFN-gamma, IL-3, and IL-5 by liver cells was also markedly reduced after i.n. treatment of CTB-Sm28GST, whereas IL-4 production was not impaired. Intranasal treatment of infected mice with CTB-Sm28GST increased IgG1-, IgG2a-, IgA-, and IgE-Ab-forming cell responses in liver in comparison with treatment with CTB-OVA, or free Sm28GST. Most importantly, mucosal treatment with CTB-Sm28GST significantly reduced animal mortality when administered to chronically infected mice. Our results suggest that it may be possible to design a therapeutic vaccine against schistosomiasis that both limits infection and suppresses parasite-induced pathology.
Department of Medical Microbiology and Immunology, University of Göteborg, Sweden. jia-bin.sun@microbio.gu.se
J B
JB
Sun
N
N
Mielcarek
M
M
Lakew
J M
JM
Grzych
A
A
Capron
J
J
Holmgren
C
C
Czerkinsky
D000281:Administration, Intranasal; D000818:Animals; D000909:Antibodies, Helminth / Q000096:biosynthesis; D000947:Antigens, Helminth / Q000276:immunology; D002772:Cholera Toxin; D002908:Chronic Disease; D016207:Cytokines / Q000096:biosynthesis; D005260:Female; D005982:Glutathione Transferase / Q000276:immunology*; D015769:Granuloma, Respiratory Tract / Q000276:immunology / Q000401:mortality / Q000469:parasitology / Q000473:pathology; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008099:Liver / Q000378:metabolism / Q000473:pathology; D008109:Liver Diseases, Parasitic / Q000276:immunology / Q000401:mortality / Q000469:parasitology / Q000473:pathology; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D009297:Nasal Mucosa / Q000276:immunology; D010270:Parasite Egg Count; D012550:Schistosoma mansoni / Q000276:immunology*; D012555:Schistosomiasis mansoni / Q000276:immunology* / Q000401:mortality / Q000469:parasitology / Q000473:pathology*; D013154:Spleen / Q000378:metabolism / Q000473:pathology; D014121:Toxoids / Q000276:immunology*; D018074:Vaccines, Conjugate / Q000008:administration & dosage / Q000276:immunology; D014734:Vibrio cholerae / Q000276:immunology*
D000909:Antibodies, Helminth; D000947:Antigens, Helminth; D016207:Cytokines; D007166:Immunosuppressive Agents; D014121:Toxoids; D018074:Vaccines, Conjugate; C038458:cholera toxoid; D002772:Cholera Toxin; D005982:Glutathione Transferase